NCI Tech Opportunity Webinar: Use of Tempol as an Antiviral Therapeutic Against COVID-19

Published on :

Attendees will hear from NICHD’s Dr. Tracey Rouault about the potential to formulate the compound, Tempol, into a preventative and oral treatment for COVID-19. The replication of the SARS-CoV-2’s genome [….]

Tonix Pharmaceuticals Announces Agreement to Acquire Infectious Disease R&D Facility in Frederick, MD to Accelerate Development of Vaccines and Antiviral Drugs

Published on :

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the signing of a Purchase and Sale Agreement to acquire an approximately 48,000 square foot research and development (R&D) facility in Frederick, MD to support Tonix’s expanding infectious disease pipeline, including TNX-1800, a live replicating viral vaccine designed to protect against COVID-19, TNX-801, a live vaccine designed to protect against smallpox and monkeypox, and TNX-3500, a small molecule antiviral to inhibit replication of SARS-CoV-2.